Use of
The present disclosure provides novel uses of Bifidobacterium lactis BL-99 in anti-aging and improving innate immunity. The Bifidobacterium lactis strain according to the present disclosure has a deposit number of CGMCC 15650. It is discovered in the present disclosure that this strain alone has an anti-aging effect, is capable of improving innate immunity of an organism, and is capable of enhancing resistance of an organism to Staphylococcus aureus infection, thereby providing use of the Bifidobacterium lactis strain of deposit number CGMCC 15650 in preparation of a composition having an anti-aging effect, capable of improving innate immunity of an organism, and/or capable of enhancing resistance of an organism to Staphylococcus aureus infection.
1 . A method for anti-immune aging, and/or enhancing resistance of an organism to Staphylococcus aureus infection to improve innate immunity of an organism, wherein the organism is an animal or a human, the method comprising:
administering an effective amount of a Bifidobacterium lactis strain to an organism, wherein the Bifidobacterium lactis strain is Bifidobacterium lactis of deposit number CGMCC 15650.
2 . The method according to claim 1 , wherein the enhancing resistance of an organism to Staphylococcus aureus infection comprises: enhancing an individual's ability to prevent Staphylococcus aureus infection, and/or alleviating food poisoning, enteritis, pneumonia, skin infection, wound ulceration and/or meningitis caused by Staphylococcus aureus infection in an individual.
3 . The method according to claim 1 , wherein the Bifidobacterium lactis strain is administered in an amount of 1.0×10 3 CFU to 1.0×10 12 CFU per day.
4 . The method according to claim 1 , wherein the Bifidobacterium lactis strain is used in a form of a solid or liquid bacterial preparation for preparing a composition; the composition comprises a food composition, a feed composition, a cosmetic composition, or a pharmaceutical composition.
5 . The method according to claim 4 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable auxiliary comprising an excipient, a diluent, a filler and/or an absorption enhancer.
6 . The method according to claim 4 , wherein the food composition comprises powder, lozenges, granules, microcapsules, or liquid formulations.
7 . The method according to claim 1 , wherein the Bifidobacterium lactis strain is for use in relieving food poisoning, enteritis, pneumonia, skin infection, wound ulceration and/or meningitis caused by Staphylococcus aureus infection;
wherein the Bifidobacterium lactis strain is administered in an amount of 1.0×10 3 CFU to 1.0×10 12 CFU per day.
8 . The method according to claim 1 , wherein the Bifidobacterium lactis strain is used in a form of a food composition.
9 . The method according to claim 8 , wherein the food is a fermented dairy product, cheese, a milk-containing beverage, a solid beverage, or milk powder.
10 . The method according to claim 1 , wherein the Bifidobacterium lactis strain is administered in an amount of 1.0×10 7 CFU to 1.0×10 11 CFU per day.
11 . The method according to claim 1 , wherein the Bifidobacterium lactis strain is for use in relieving food poisoning, enteritis, pneumonia, skin infection, wound ulceration and/or meningitis caused by Staphylococcus aureus infection;
wherein the Bifidobacterium lactis strain is administered in an amount of 1.0×10 7 CFU to 1.0×10 11 CFU per day.